Aliases & Classifications for Pituitary Tumors

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 50 51 40
Pituitary Neoplasms 69

Classifications:



External Ids:

UMLS 69 C0032019

Summaries for Pituitary Tumors

NINDS : 50 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to prolactin producing pituitary tumor and tsh producing pituitary tumor. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Relaxin signaling pathway and PI3K-Akt signaling pathway. The drugs Dopamine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

MedlinePlus : 40 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 33.8 PRL SST
2 tsh producing pituitary tumor 33.6 GH1 PRL SST
3 empty sella syndrome 32.0 GH1 POMC PRL
4 gigantism 31.9 AIP GH1 PRL
5 pituitary apoplexy 31.6 AIP POMC PRL
6 acth-secreting pituitary adenoma 31.4 GNAS POMC PRL
7 pituitary adenoma 1, multiple types 31.3 AIP GH1 IGF1 PRL SST
8 hormone producing pituitary cancer 31.3 AIP GNAS IGF1 MEN1 SST
9 galactorrhea 30.2 IGF1 PRL
10 non-functioning pituitary adenoma 29.9 GH1 SST
11 pituitary carcinoma 29.9 GNAS POMC SST
12 multiple endocrine neoplasia, type i 29.8 GNAS MEN1 PRL SST
13 lymphocytic hypophysitis 29.8 GH1 POMC
14 hyperthyroidism 29.7 GH1 GNAS PRL SST
15 insulin-like growth factor i 29.6 GH1 IGF1 PRL SST
16 adenohypophysitis 29.5 GH1 POMC PRL
17 growth hormone deficiency 29.4 GH1 IGF1 PROP1
18 chiasmal syndrome 29.3 POMC PRL SST
19 nelson syndrome 29.3 POMC PRL SST
20 pituitary hypoplasia 29.2 POU1F1 PRL
21 thyroid carcinoma, familial medullary 29.2 MEN1 SST SSTR5
22 growth hormone secreting pituitary adenoma 29.2 AIP GNAS PRL SST
23 small cell cancer of the lung 29.1 POMC RB1 SST
24 craniopharyngioma 29.0 IGF1 POU1F1 PRL PROP1
25 mccune-albright syndrome 29.0 GH1 GNAS IGF1 PRL SST
26 hyperprolactinemia 28.8 GH1 IGF1 POMC PRL SST
27 pheochromocytoma 28.7 MEN1 POMC SST
28 pituitary gland disease 28.7 GH1 IGF1 MEN1 POMC POU1F1 PRL
29 body mass index quantitative trait locus 11 28.7 GH1 GNAS IGF1 POMC
30 carney complex variant 28.5 AIP GNAS MEN1 POMC
31 functioning pituitary adenoma 27.8 AIP GH1 MEN1 POMC PRL SST
32 pituitary hormone deficiency, combined, 2 27.8 GH1 IGF1 POMC POU1F1 PRL PROP1
33 hypopituitarism 27.8 GH1 IGF1 POMC POU1F1 PRL PROP1
34 adenoma 27.7 AIP GH1 GNAS IGF1 MEN1 POMC
35 acromegaly 27.6 AIP GH1 GNAS IGF1 MEN1 POMC
36 pituitary adenoma, prolactin-secreting 27.4 AIP GH1 GNAS IGF1 MEN1 POMC
37 pituitary adenoma 26.7 AIP GH1 GNAS IGF1 MEN1 POMC
38 secondary adrenal insufficiency 11.2
39 posterior pituitary gland neoplasm 10.9
40 acth-independent macronodular adrenal hyperplasia 10.8
41 primary pigmented nodular adrenocortical disease 10.8
42 fibrous dysplasia/mccune-albright syndrome 10.5 GH1 PRL
43 ovarian cyst 10.4 PRL VEGFA
44 chronic mountain sickness 10.4 SST VEGFA
45 angiodysplasia 10.4 SST VEGFA
46 villous adenoma 10.4 GNAS SST
47 adenomyosis 10.4 PRL VEGFA
48 mammographic density 10.3 IGF1 PRL
49 pancreatic endocrine carcinoma 10.3 SST SSTR5
50 peripartum cardiomyopathy 10.3 PRL VEGFA

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.22 IGF1 MEN1 POMC POU1F1 PRL PROP1
2 homeostasis/metabolism MP:0005376 10.21 AIP GNAS IGF1 MEN1 POMC POU1F1
3 growth/size/body region MP:0005378 10.2 AIP GNAS IGF1 MEN1 POMC POU1F1
4 immune system MP:0005387 10.06 GNAS IGF1 MEN1 POMC POU1F1 PRL
5 mortality/aging MP:0010768 9.96 AIP GNAS IGF1 MEN1 POMC POU1F1
6 integument MP:0010771 9.91 POMC PRL RB1 VEGFA AIP GNAS
7 liver/biliary system MP:0005370 9.87 PRL RB1 VEGFA AIP GNAS MEN1
8 neoplasm MP:0002006 9.76 AIP GNAS IGF1 MEN1 POMC PRL
9 nervous system MP:0003631 9.65 GNAS IGF1 MEN1 POMC POU1F1 PRL
10 reproductive system MP:0005389 9.17 IGF1 MEN1 POU1F1 PRL PROP1 RB1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 657311 5754
3
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
4
Menthol Approved Phase 4 2216-51-5 16666
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
10 lanreotide Approved Phase 4,Phase 3 108736-35-2
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
13
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
15
Metformin Approved Phase 4 657-24-9 4091 14219
16
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Liraglutide Approved Phase 4 204656-20-2 44147092
20
Cefazolin Approved Phase 4 25953-19-9 33255 656510
21
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
22
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
23
Cefdinir Approved Phase 4 91832-40-5 6915944
24
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
26
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
27
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
28 glucocorticoids Phase 4,Phase 2,Phase 1
29 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
30 Central Nervous System Depressants Phase 4,Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Cortisol succinate Phase 4,Phase 3,Phase 2
33 Anesthetics Phase 4,Phase 1
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
39 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
40 Hydrocortisone-17-butyrate Phase 4
41 Hypnotics and Sedatives Phase 4,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
43 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
44 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
45 insulin Phase 4,Phase 3,Phase 2
46 Analgesics Phase 4
47
protease inhibitors Phase 4,Phase 1
48 Narcotics Phase 4
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Cyclooxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 137)

# Name Status NCT ID Phase Drugs
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
4 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
5 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
6 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
7 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
8 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
9 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
10 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
11 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
12 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
13 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
14 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
15 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
16 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
17 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
18 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
19 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
20 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide (SOM230);octreotide LAR 30mg;lanreotide ATG 120mg
21 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
22 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
23 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
24 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 SOM230 LAR 30 mg;SOM230 LAR 10 mg
25 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
26 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
27 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
28 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
29 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
30 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
31 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
32 Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Terminated NCT00642421 Phase 3 C2L-OCT-01 PR, 10 or 20 mg;C2L-OCT-01 PR, 20 mg
33 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
34 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
35 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
36 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
37 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
38 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
39 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
40 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
41 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
42 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
43 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
44 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Recruiting NCT01283542 Phase 2 Pasireotide LAR
45 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
46 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
47 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
48 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
49 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
50 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

MalaCards organs/tissues related to Pituitary Tumors:

38
Pituitary, Brain, Thyroid, Testes, Hypothalamus, Ovary, Adrenal Gland

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 856)
# Title Authors Year
1
Management of nonfunctioning pituitary tumors: radiotherapy. ( 29372392 )
2018
2
Baculovirus-based gene silencing of Humanin for the treatment of pituitary tumors. ( 29352443 )
2018
3
Expression of MMP-9, PTTG, HMGA2, and Ki-67 in ACTH-secreting pituitary tumors and their association with tumor recurrence. ( 29432944 )
2018
4
Excellence in the treatment of patients with pituitary tumors. ( 29124563 )
2018
5
Genomic Alterations in Sporadic Pituitary Tumors. ( 29396598 )
2018
6
Transsphenoidal Surgery for Pituitary Tumors and Other Sellar Masses. ( 29056398 )
2018
7
Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients. ( 28789441 )
2017
8
A Comparison of Dexmedetomidine and Clonidine in Attenuating the Hemodynamic Responses at Various Surgical Stages in Patients Undergoing Elective Transnasal Transsphenoidal Resection of Pituitary Tumors. ( 29284879 )
2017
9
Recent Progress in the Medical Therapy of Pituitary Tumors. ( 28685507 )
2017
10
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. ( 28120505 )
2017
11
First Report of Coexistence of Two Ectopic Pituitary Tumors: Rathke Cleft Cyst and Silent Adrenocorticotropic Hormone Adenoma. ( 28532906 )
2017
12
Acute hypopituitarism associated with periorbital swelling and cardiac dysfunction in a patient with pituitary tumor apoplexy: a case report. ( 28835258 )
2017
13
Pregnancy promotes pituitary tumors by increasing the rate of the cell cycle. ( 29085495 )
2017
14
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. ( 28432119 )
2017
15
Assessment of Cost Drivers in Transsphenoidal Approaches for Resection of Pituitary Tumors Using the Value-Driven Outcome Database. ( 28583451 )
2017
16
The Stem Cell Connection of Pituitary Tumors. ( 29255445 )
2017
17
Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report. ( 28072724 )
2017
18
A case of central pontine and extrapontine myelinolysis after surgery for a pituitary tumor. ( 27980288 )
2017
19
MicroRNAs in pituitary tumors. ( 28089822 )
2017
20
Corticotroph pituitary carcinoma in a patient with Lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort. ( 28938458 )
2017
21
Neuroretinal evaluation using optical coherence tomography in patients affected by pituitary tumors. ( 28447589 )
2017
22
Overview of the 2017 WHO Classification of Pituitary Tumors. ( 28766057 )
2017
23
FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. ( 27966451 )
2017
24
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. ( 28486603 )
2017
25
Non-functioning pituitary tumors: any special considerations during pregnancy? ( 29265782 )
2017
26
Transient Exacerbation of Nasal Symptoms following Endoscopic Transsphenoidal Surgery for Pituitary Tumors: A Prospective Study. ( 28593114 )
2017
27
Prognostic factors of regrowth in nonfunctioning pituitary tumors. ( 29288467 )
2017
28
Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. ( 28711607 )
2017
29
Authors' Reply: Comprehensive neuro-ophthalmological assessment in pituitary tumors. ( 28488670 )
2017
30
Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. ( 29043561 )
2017
31
Full-field perimetry in pituitary tumors. ( 28488669 )
2017
32
Integrated in silico-in vitro characterization, identification and disruption of the intermolecular interaction between SH3 domain-containing protein kinases and human pituitary tumor-transforming gene 1. ( 27787230 )
2017
33
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. ( 27655724 )
2016
34
Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. ( 27600151 )
2016
35
Molecular markers in pituitary tumors. ( 27254269 )
2016
36
Multimodal Navigation in Endoscopic Transsphenoidal Resection of Pituitary Tumors using Image-based Vascular and Cranial Nerve Segmentation: A Prospective Validation Study. ( 27302558 )
2016
37
Magnetic Resonance Imaging of Pituitary Tumors. ( 27003878 )
2016
38
Endoscopic Approach to Pituitary Tumors. ( 26626930 )
2016
39
Resection of pituitary tumors: endoscopic versus microscopic. ( 27161249 )
2016
40
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. ( 26983879 )
2016
41
Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. ( 26721946 )
2016
42
Pituitary tumor transforming gene-1 in non-small cell lung cancer: Clinicopathological and immunohistochemical analysis. ( 27829547 )
2016
43
Letter to the Editor: Pituitary tumors and cavernous sinus extension. ( 26848910 )
2016
44
The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor. ( 26676407 )
2016
45
Advances in Gamma Knife radiosurgery for pituitary tumors. ( 27341278 )
2016
46
Radiation Therapy in the Management of Pituitary Tumors. ( 26626931 )
2016
47
The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. ( 27815769 )
2016
48
The role of microRNAs in the pathogenesis of pituitary tumors. ( 26709756 )
2016
49
Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary tumors: systematic review and meta-analysis of randomized and non-randomized controlled trials. ( 27598981 )
2016
50
A Case of Optic Neuritis Concomitant with Pituitary Tumor During Pregnancy. ( 27373939 )
2016

Variations for Pituitary Tumors

Cosmic variations for Pituitary Tumors:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,functioning c.133T>C p.S45P 4

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 GH1 GNAS IGF1 POMC PRL SST
2 endosome lumen GO:0031904 8.62 GH1 PRL

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.88 MEN1 POU1F1 PROP1 RB1 VEGFA
2 negative regulation of cell proliferation GO:0008285 9.65 MEN1 POU1F1 RB1 SST SSTR5
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 GH1 IGF1 VEGFA
4 regulation of multicellular organism growth GO:0040014 9.56 IGF1 PRL
5 positive regulation of receptor internalization GO:0002092 9.55 GH1 VEGFA
6 myoblast differentiation GO:0045445 9.54 IGF1 RB1
7 tissue homeostasis GO:0001894 9.52 GNAS RB1
8 positive regulation of JAK-STAT cascade GO:0046427 9.51 GH1 PRL
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 GH1 IGF1 VEGFA
10 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 IGF1 MEN1 POMC POU1F1 PROP1 RB1
11 positive regulation of transcription regulatory region DNA binding GO:2000679 9.49 IGF1 RB1
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.46 GH1 PRL
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 IGF1
14 adenohypophysis development GO:0021984 9.37 POU1F1 PROP1
15 somatotropin secreting cell differentiation GO:0060126 9.16 POU1F1 PROP1
16 regulation of receptor activity GO:0010469 9.1 GH1 IGF1 POMC PRL SST VEGFA

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 GH1 IGF1 VEGFA
2 insulin-like growth factor receptor binding GO:0005159 9.16 GNAS IGF1
3 hormone activity GO:0005179 9.02 GH1 IGF1 POMC PRL SST
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....